Fondazione IRCCS Policlinico San Matteo di Pavia: Amyloidosis trials

The registry lists 14 Amyloidosis studies with Fondazione IRCCS Policlinico San Matteo di Pavia as lead sponsor. 3 are open to participants now and 0 have results posted.

Phase 2 7Phase 3 2No phase 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• An Interventional Pilot Study to Investigate the Feasibility and Acceptance of a Structured Psychological Support Program for Patients, Caregivers, and Presymptomatic Carriers in Hereditary Transthyretin Amyloidosis With CardiomyopathyRecruitingNCT06907186Not applicable
• The Italian Transthyretin Amyloidosis Web-NetworkRecruitingNCT05444920
• A Registry of AL Amyloidosis (ReAL)RecruitingNCT04839003
• Daratumumab and Pomalidomide in Previously Treated Patients With AL AmyloidosisTerminatedNCT04895917Phase 2
• Novel Imaging Tools in Newly-diagnosed Patients With Cardiac AL AmyloidosisCompletedNCT04392960Not applicable
• A Study of Doxycycline and Tauroursodeoxycholic Acid (Doxy/TUDCA) Plus Standard Supportive Therapy Versus Standard Supportive Therapy Alone in Cardiac Amyloidosis Caused by TransthyretinCompletedNCT03481972Phase 3
• A Trial of Doxycycline vs. Standard Supportive Therapy in Newly-diagnosed Cardiac AL Amyloidosis Patients Undergoing Bortezomib-based TherapyTerminatedNCT03474458Phase 2/3
• Body Composition in Systemic AmyloidosisCompletedNCT02111538
• Nutritional Counseling in Systemic Immunoglobulin Light-chain AmyloidosisCompletedNCT02055534Not applicable
• High Cut-off Hemodialysis in Patients With Advanced Cardiac AL Amyloidosis and End Stage Renal DiseaseWithdrawnNCT01531751Phase 2
• Epigallocatechingallate (EGCG) in Cardiac AL AmyloidosisTerminatedNCT01511263Phase 2
• Pomalidomide and Dexamethasone (PDex) in AL AmyloidosisCompletedNCT01510613Phase 2
• Safety, Efficacy and Pharmacokinetics of Doxycycline Plus Tauroursodeoxycholic Acid in Transthyretin AmyloidosisCompletedNCT01171859Phase 2
• Cyclophosphamide, Lenalidomide and Dexamethasone (CLD) for Previously Treated Patients With AL AmyloidosisCompletedNCT00607581Phase 2